Stock Monitor: DelMar Pharma Post Earnings Reporting
LONDON, UK / ACCESSWIRE / May 30, 2018 / If you want access to our free research report on Keryx Biopharma, Inc. (NASDAQ: KERX) ("Keryx"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=KERX as the Company's latest news hit the wire. On May 25, 2018, the Company shared the data from an investigator sponsored clinical trial that showed the impact of the use of ferric citrate in treating patients with advanced chronic kidney disease (CKD). The Company presented the results at the recently-held 55th ERA-EDTA Congress held at Copenhagen, Denmark, from May 24, 2018, to May 27, 2018. Register today and get access to over 1,000 Free Research Reports by joining our site below:
Active-Investors.com is currently working on the research report for DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), which also belongs to the Healthcare sector as the Company Keryx Biopharma. Do not miss out and become a member today for free to access this upcoming report at:
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Keryx Biopharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
Details of the Clinical Study
The clinical trial was an open-label, single-center study that evaluated the use of ferric citrate in treating late-stage non-dialysis dependent CKD patients compared to the standard of care treatment (SOC). The clinical trial was conducted on patients who had an eGFR < 20 ml/min and who were not expected to start renal replacement therapy (dialysis) within 8 weeks of the start of the study. The patients were randomly segregated into two groups in the ratio of 2:1. One group received a fixed dose of ferric citrate (two tablets per meal), and the second group received SOC. A total of 199 patients were chosen for the study, of which 133 were treated with ferric citrate while the balance 66 patients were treated with SOC. Nearly 37% of the patients treated with SOC received phosphate binders during the pre-dialysis period. The patients who were a part of this trial were observed monthly for a nine-month period, whereas those patients who had started the dialysis treatment were observed three months after the start of dialysis. The data presented by the Company refers to the statistics from the non-dialysis period of the trial. This includes those patients who were observed for nine months and did not progress to dialysis or the time leading up to dialysis for patients who progressed.
Results of the Clinical Study
While analyzing the data from the clinical trial, the Company used many biochemical parameters associated with CKD, viz., hemoglobin, transferrin saturation (TSAT), ferritin, phosphorus, and intact-FGF23 in all the enrolled patients. At baseline, these parameters were consistent between the treatment groups. However, there were more diabetic patients who were randomly assigned to receive the SOC treatment.
Out of the 133 patients who were chosen to receive ferric citrate treatment, 76 patients completed the full nine months of the study; 30 patients started renal replacement therapy; 16 patients terminated early; 8 patients received a transplant; and 3 patients died.
In the 66 patients' group that received SOC treatment, 29 patients completed the nine months of the study; 31 patients started renal replacement therapy; 4 patients terminated early; and 2 patients died.
At the end of the nine months of the clinical trial, patients who had received the ferric citrate during the non-dialysis period showed significant improvements across all biochemical parameters of the trial compared to those patients who were treated with SOC. Overall, when comparing the patients progress towards death, dialysis, or transplant in each treatment scenario, it was noticed that patients who were treated with ferric citrate were less likely to reach dialysis or death.
Commenting on the results of the clinical study, Geoffrey Block, M.D, Director of Clinical Research at Denver Nephrology, said:
"The data from this study suggest that administering ferric citrate to late-stage pre-dialysis patients not only improves biochemical parameters associated with chronic kidney disease, but also has the potential to delay the need for dialysis. With the impact of ferric citrate across multiple aspects of CKD, it is worth further investigation to determine which of these many factors is contributing to the reduced risk of renal replacement therapy observed in this study."
About Auryxia (ferric citrate) Tablets
Keryx's Auryxia (ferric citrate) tablets received approval from the US Food and Drug Administration (FDA) in September 2014 for the control of serum phosphorus levels in adult patients with CKD on dialysis, followed by the FDA's approval in November 2017 for Auryxia for the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. These tablets contain 210 mg of ferric iron, equivalent to 1 gram of ferric citrate, and offers convenient mealtime dosing. The starting dose of Auryxia for the treatment of hyperphosphatemia for patients on dialysis is six tablets per day (two per meal), whereas for the treatment of iron deficiency anemia in patients not on dialysis, it is three tablets per day (one per meal).
About Keryx Biopharmaceuticals, Inc.
Boston, Massachusetts-based Keryx is focused on bringing innovative medicines to people with kidney disease. The Company has been operating for over 20 years and has 200 employees, consisting mostly of kidney care experts, including nephrologists, renal dietitians, nurses, and industry veterans in nephrology to jointly raise awareness of the kidney disease epidemic, give voice to this underserved population, and help healthcare professionals to improve the care of their patients.
Stock Performance Snapshot
May 29, 2018 - At Tuesday's closing bell, Keryx Biopharma's stock climbed 1.14%, ending the trading session at $5.31.
Volume traded for the day: 1.14 million shares.
Stock performance in the last month – up 11.09%; previous three-month period – up 11.32%; past six-month period – up 9.94%; and year-to-date - up 14.19%
After yesterday's close, Keryx Biopharma's market cap was at $636.37 million.
The stock is part of the Healthcare sector, categorized under the Biotechnology industry.
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst. For further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.